Mirae Asset Global Investments Co. Ltd. Has $48.41 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 19.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 345,074 shares of the company’s stock after buying an additional 55,880 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Johnson & Johnson were worth $48,410,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Jericho Financial LLP acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $427,000. Hager Investment Management Services LLC bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $297,000. Cassia Capital Partners LLC grew its holdings in Johnson & Johnson by 59.5% during the 4th quarter. Cassia Capital Partners LLC now owns 5,538 shares of the company’s stock worth $801,000 after acquiring an additional 2,065 shares during the last quarter. Avitas Wealth Management LLC increased its position in Johnson & Johnson by 0.6% in the 4th quarter. Avitas Wealth Management LLC now owns 30,181 shares of the company’s stock valued at $4,365,000 after acquiring an additional 182 shares during the period. Finally, Redwood Wealth Management Group LLC lifted its holdings in shares of Johnson & Johnson by 3.2% during the fourth quarter. Redwood Wealth Management Group LLC now owns 4,020 shares of the company’s stock worth $580,000 after purchasing an additional 124 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Bank of America decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Guggenheim boosted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Barclays upped their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Finally, Citigroup cut their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $153.10 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a market capitalization of $368.61 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. The stock has a fifty day simple moving average of $147.46 and a 200 day simple moving average of $156.06. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.29 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.